693 completed, 334 unknown, 255 terminated, 139 withdrawn. 1513 Phase 2, 278 Phase 3, 268 Phase 1.
Follow Coronavirus Infections: new trials by email Literature Review of Coronavirus Infections trials Research Report on Coronavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19 | Phase 1 / Phase 2 | Not yet recruiting | Kimera Labs Inc. | 64 | 2027-01-01 | 2026-06-24 |
| Taurine Supplementation in Adolescents With Post-COVID Condition Taurine - Long COVID, Post COVID-19 Condition | Phase 1 / Phase 2 | Not yet recruiting | University of Alberta | 30 | 2026-12-30 | 2026-10-16 |
| CD19-B Cell Depletion in PAIS-ME/CFS Patients Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID) | Phase 2 | Not yet recruiting | Charite University, Berlin, Germany | 38 | 2026-12-01 | 2026-07-24 |
| Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome Rimonabant, Placebo - Post-COVID-19 Syndrome | Phase 2 | Not yet recruiting | Sinfatin S.L | 80 | 2026-11-06 | 2026-11-12 |
| SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction Valacyclovir, Celecoxib, Paxlovid - Post-acute Sequelae of COVID-19, Long COVID | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 150 | 2026-10-20 | 2026-10-28 |
| Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE) Aripiprazole (low-dose, 1mg), Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID) | Phase 2 | Not yet recruiting | Christiana Franke | 138 | 2026-10-01 | 2026-07-20 |
| Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome VYD2311, Placebo - Long COVID, COVID-19 (SARS-CoV-2 Infection) | Phase 2 | Not yet recruiting | Invivyd, Inc. | 130 | 2026-10-01 | 2026-10-27 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age mRNA-1283, mRNA-1273 - SARS-CoV-2 | Phase 2 | Recruiting | ModernaTX, Inc. | 300 | 2026-09-04 | 2026-11-09 |
| A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc - Long COVID | Phase 2 / Phase 3 | Not yet recruiting | HealthBio, Inc. | 252 | 2026-07-15 | 2026-06-18 |
| Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS Human umbilical cord mesenchymal stem cells + best supportive care, Placebo control + best supportive care - COVID-19, ARDS | Phase 1 / Phase 2 | Withdrawn | Baylx Inc. | 2026-06-01 | 2025-12-29 | |
| Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID Paragon Novel Metabolic Regulator (PNMR), Dietary and Lifestyle Recommendations - Long COVID | Phase 2 | Recruiting | ParagonClinicals Inc. | 82 | 2026-05-20 | 2026-06-04 |
| DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine - Tinnitus | Phase 2 | Enrolling by invitation | Leading Edge Clinic | 20 | 2026-05-15 | 2026-05-13 |
| Sonlicromanol in Post-COVID Sonlicromanol, Placebo - Post COVID Condition | Phase 2 | Recruiting | Michele van Vugt | 80 | 2026-04-03 | 2026-08-18 |
| Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome Instilled T3, Placebo Therapy - Covid19, SARS-CoV Infection | Phase 2 | Withdrawn | University of Minnesota | 2026-01-15 | 2026-02-10 | |
| Immunoadsorption in Autoimmune Long COVID Immunoadsorption, Sham Comparator - Long COVID, Long COVID Syndrome | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 70 | 2026-01-01 | 2026-11-10 |
| Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment - Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS) | Phase 2 | Recruiting | Vanderbilt University Medical Center | 50 | 2025-12-18 | 2026-01-22 |
| "Efesovir" (FS-1) for COVID-19, Phase 2 Efesovir - Covid19 | Phase 2 | Not yet recruiting | Scientific Center for Anti-infectious Drugs, Kazakhstan | 62 | 2025-12-01 | 2024-04-17 |
| Taurine Supplementation in Long COVID Taurine, Placebo - Long COVID | Phase 2 / Phase 3 | Recruiting | University of Alberta | 300 | 2025-11-18 | 2026-09-18 |
| A Study to Assess Anktiva in Patients With Long Covid-19. N-803 (IL-15 Superagonist) - Long COVID | Phase 2 | Recruiting | ImmunityBio, Inc. | 20 | 2025-11-14 | 2026-05-11 |
| Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine - COVID-19 | Phase 2 | Active not recruiting | CastleVax Inc. | 200 | 2025-11-03 | 2026-07-22 |
Showing 20 of 1513. Sign in to see all of them.
COVID-19 (1391) · Post-Acute COVID-19 Syndrome (94) · Respiratory Distress Syndrome (80) · Severe Acute Respiratory Syndrome (78) · Pneumonia (72) · Virus Diseases (41) · Cytokine Release Syndrome (39) · Pneumonia, Viral (32) · Respiratory Insufficiency (26) · Influenza, Human (17) · Acute Lung Injury (16) · Infections (15) · Respiratory Tract Infections (15) · Anosmia (13)
Nidovirales Infections (1508) · Coronaviridae Infections (1507) · RNA Virus Infections (1505) · Infections (1498) · Respiratory Tract Diseases (1476) · Virus Diseases (1472) · Respiratory Tract Infections (1461) · Lung Diseases (1455) · Pneumonia, Viral (1427) · Pneumonia (1390) · Pathological Conditions, Signs and Symptoms (222) · Pathologic Processes (194) · Disease Attributes (119) · Respiration Disorders (106)
Standard of Care (78) · Hydroxychloroquine (65) · Saline Solution (46) · Sodium Chloride (46) · BNT162 Vaccine (39) · Ivermectin (27) · Ritonavir (25) · 2019-nCoV Vaccine mRNA-1273 (24) · Azithromycin (24) · remdesivir (18) · nitazoxanide (17) · favipiravir (16) · COVID-19 Serotherapy (15) · COVID-19 Vaccines (15) · ChAdOx1 nCoV-19 (15)
Sinocelltech Ltd. (17) · Sorrento Therapeutics, Inc. (15) · Assistance Publique - Hôpitaux de Paris (14) · BioNTech SE (13) · National Institute of Allergy and Infectious Diseases (NIAID) (13) · Novavax (11) · Pfizer (11) · ModernaTX, Inc. (10) · Stanford University (10) · Washington University School of Medicine (10) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (9) · AstraZeneca (8) · Massachusetts General Hospital (8) · The University of Hong Kong (8) · ANRS, Emerging Infectious Diseases (7)
United States (516) · Brazil (103) · Spain (87) · China (83) · Mexico (60) · France (59) · Canada (56) · United Kingdom (55) · Italy (54) · Germany (51) · Russia (49) · South Africa (48) · Argentina (37) · South Korea (31) · Colombia (30)
Mike Royal, MD (14) · Teresa Prat (6) · Mikhail Samsonov (5) · Fengcai Zhu, Doctor (4) · Ivan FN Hung, MD FRCP (4) · Lorenzo Berra, MD (4) · Bill Arana (3)
PMID 34473343, PMID 35713300, PMID 34013969, PMID 36734509, PMID 37162745, PMID 35244208, PMID 34658014, PMID 31986264, PMID 32031570, PMID 32171076, PMID 32109013, PMID 32142651, PMID 33502773, PMID 39903535, PMID 32192578, PMID 32788708, PMID 33044747, PMID 40592258, PMID 29515037, PMID 32112977, PMID 32205204, PMID 32251768, PMID 32738928, PMID 33306989, PMID 33617777, PMID 33754144, PMID 36700518, PMID 37489818, PMID 38077399, PMID 41720282, PMID 11756340, PMID 11960602, PMID 12086935, PMID 15141377, PMID 16308421, PMID 17941868, PMID 22974412, PMID 23053510, PMID 23208422, PMID 25030060, PMID 29859173, PMID 31978293, PMID 31986257, PMID 32020029, PMID 32085846, PMID 32091533, PMID 32125455, PMID 32150618, PMID 32167524, PMID 32171740
2023 (8), P30CA033572 (3), 2025 (2), UL1TR001412 (2), 1ZIDES102465 (1), 2017 (1), 2019 (1), 272201800011C-P00005-9999-1 (1), 2UG1CA189859-06 (1), 3UH3DK114920-04S2 (1), 5UM1AI148684-02 (1), 5UM1AI148684-03 (1), I21RX004409 (1), P30CA013330 (1), P30CA138292 (1)